Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2014

View Archived Issues

Phase II results for the influenza A/H7N9 vaccine in combination with an adjuvant

Shionogi recaps highlights of second quarter of fiscal 2014

Novel genetic biomarkers of human malformation disorders

Sumitomo Dainippon Pharma reviews second quarter of fiscal 2014

Sanofi presents highlights of third quarter 2014

Researchers present novel targets and biomarkers in pancreatic cancer

FDA orphan drug status granted to oprozomib for multiple myeloma

Sodium thiosulfate designated orphan drug by the FDA

Glioma candidate pritumumab receives U.S. orphan drug designation

MPDL-3280A well tolerated in phase Ia trial in patients with mRCC

EMA publishes revised guideline on biosimilars

EMA releases third and final module on influenza vaccine guidance for public consultation

Chugai licenses EpiVax de-immunization technologies to optimize biologics pipeline

Swiss approval to begin Ebola vaccine trial

Award supports Verona Pharma's exploration of RPL-554 for cystic fibrosis

New PDE4B inhibitors reported by Gruenenthal

Esteve presents novel ligands of sigma receptors

Guangzhou Baiyunshan Pharmaceutical synthesizes tricyclic quinolones

Canadian company presents CRP40 fragments for neurological disorders

Glenmark Pharmaceuticals reports novel mPGES-1 inhibitors

New GnRH receptor antagonists discovered at Bayer Schering Pharma

Salix and Pharming launch Ruconest in the U.S. for acute angioedema attacks in HAE

Novartis plans phase I/II trial of Wnt-targeting drug regimen in BRAF-mutant colorectal cancer

Arena Pharmaceuticals to test APD-811 in patients with pulmonary arterial hypertension

Nymox's NX-1207 fails to achieve efficacy endpoints in phase III BPH trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...